


Veeda Biopharma Integrated Solutions

NCE | NBE | BIOSIMILARS | VACCINES



Bridging Ideas to Impact,
one Biopharmaceutical Breakthrough at a time

About Us

Veeda Clinical Research Limited (“Veeda”) together with its subsidiary, Bionees India Private Limited (“Bionees”) (together referred to as the “Veeda Group”) offers a comprehensive portfolio of clinical, preclinical and biopharma services to support innovator, biosimilar and generic drug development programs of our global clientele. Together, we serve clients globally in the following industries:



Pharmaceutical & Biopharmaceutical



Agrochemical & Industrial Chemicals



Herbal/ Nutraceuticals



Medical Devices

US FDA → 45

MHRA → 04

ANVISA → 08

WHO → 06

**NPRA
Malaysia → 05**

ANSM → 01

AGES → 05

MCC → 01

DCGI → 19

*Veeda Group Regulatory Credentials

Biopharma Division

Biopharma division, an advanced-integrated solution partner, brings-in rich expertise of Veeda Clinical Research Ltd. and Bionees; pioneers in clinical research and preclinical studies, respectively. The expert scientific teams drawn from these two eminent organizations are fully equipped with state-of-the-art technologies to partner with leading global biopharmaceutical organization to deliver excellence. A fully integrated biopharma Contract Research & Development Organization, situated in the biotech hub of Bangalore, India with ~50,000 Sq. ft. campus. The Biopharma Division of Veeda Clinical Research caters to R&D needs of global biopharmaceutical & biotechnology clients.



Discovery Biology



Bioprocess Development



Analytics & Characterization



Clinical Bioanalysis

BioPharma Services

Discovery Biology

Biochemical and Functional Characterization

- Biochemical activity assays, Binding Assays, Target Phosphorylation assays (cell-free and cellular), cAMP assays, IP1/IP3 assays, Target degradation assays, proliferation and viability assays, Apoptosis assays, Reporter gene assays, Biomarker assays, Reporter Gene Assays, CDC and ADCC assays
- Measurement modes: Luminescence, HTRF/TRF, AlphaScreen®, LANCE/DELPHIA®, flowcytometry, multiplex, EliSpot and other technologies

Biophysical assays

- SPR: Biacore binding studies, Association and dissociation kinetics
- FcRn, FCy Binding assays

Flow Cytometry

- Receptor Binding, Immunogenicity, Immune Cell Profiling
- PD studies

Immunogenicity Assays for Drug Products

Bioprocess Development

Clone/Cell line Development

- CQA based cell line development
- Expression construct under strong promoters
- Clone selection with high cell growth and productivity

Cell line Characterization

- Stability
- Purity
- Gene copy numbers

Process Development & Optimization

- At 2 L/5 L scales
- Clones screening for Bioreactor suitability
- Optimization with critical process parameters
- Material generation for preclinical toxicity studies

Downstream Process

- Process development for purification of recombinant proteins
- Optimization for purity and higher recovery

Analytics & Characterization

Physico-chemical Characterization

- Intact & subunit molecular mass
- Peptide & disulfide mapping, sequencing
- Release glycan (N-/O-linked)
- Post translational modifications & sequence variant

Higher-Order Structure Characterization

- Secondary & tertiary structure
- Protein conformation
- Protein dynamics & stability
- Protein aggregation studies

High-throughput Characterization (ZipChip)

- Intact & Native antibodies
- Charge variants
- Metabolites
- Oligonucleotides

Analytical Services

- Method development – RP, SEC, IEX, HILIC, HIC
- Impurity identification (charge, size, HIC, HILIC)
- Impurity characterization
- Impurity enrichment

Clinical Bioanalysis

Pharmacokinetics / Pharmacodynamics Assays

- Primary and secondary clinical endpoints
- PK parameters – Cmax, Tmax, AUC, t1/2
- Biosimilar Equivalence – One assay approach
- Incurred Sample Reanalysis

Immunogenicity Assays

- Tier based approach – Regulatory Acceptance
- Screening, confirmatory and titer assays
- Functional Nab Assays - Cell based/competitive LBA

Cytokine and Biomarker Assays

- Cytokine Panel Estimations – Th1/Th2/Th17 Panels
- Disease targeted biomarker analysis
- High throughput multiplexing assays

Vaccine Immunogenicity

- Antibody titer and concentration estimations (GMT/GMC)
- Seroconversion and seropositivity estimations
- Cell based functional assays – Serum Neutralization Assays/ Serum bactericidal Assays

Our Infrastructure

Bioprocess Development

- Automated cell counter (Beckman-Coulter)
- Electroporator (Thermo)
- Inverted phase contrast microscope (Olympus)
- Bioreactors 2 L/5 L (Sartorius)
- AKTA pure 150 (Cytiva)

Discovery Biology

- Tecan SPARK
- SPR - Biacore 1S+
- Luminex Intelliplex
- EliSpot
- BD FACS Lyric
- Integra Assist Plus
- Agilent Novocyte

Analytics & Characterization

- HRMS – Waters Xevo G3 QToF & Thermo QExactive Orbitrap
- HPLC – Shimadzu Prominence
- CE – Sciex PA800 Plus
- SEC/FFF-MALS – Postnova AF2000
- CD – Chirascan V100
- FTIR – Bruker Confocheck
- DSC – TA nanoDSC
- DLS – Anton Paar Litesizer 500

Clinical Bioanalysis

- Multimode Reader – Synergy H1 (Colorimetric, Fluorescence, Luminescence)
- MSD Quickplex SQ 120 (ECL)
- Sciex 6500+ with Acquity Premier UPLC

Modalities

NCE

NBE

PROTACs

Oligos

Peptides/
Proteins

mAbs

Bispecific
ADCs

Vaccines

Veeda Group Advantage

Extensive Scientific
Competence to service a
Diverse client base

One of the largest
Independent Full
Service CROs in India

High Customer
Centricity and
Satisfaction

Robust Quality &
Regulatory
Compliance

Skilled personnel with
focus on Continuous
Professional
Development

One stop solution
for complex
studies

**Veeda Group
Advantage**



**Veeda Clinical Research Limited
(Biopharma Division)**

No. P3 & P3-A, 1st Main Road, Peenya Industrial Area,
1st Stage, Bengaluru 560058, India
Info@veedacr.com | www.veedacr.com | +91767773000

• **Partners in creating a healthier tomorrow** •